BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

211 related articles for article (PubMed ID: 31808885)

  • 1. Curing Ph+ ALL: assessing the relative contributions of chemotherapy, TKIs, and allogeneic stem cell transplant.
    Fielding AK
    Hematology Am Soc Hematol Educ Program; 2019 Dec; 2019(1):24-29. PubMed ID: 31808885
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Chemotherapy with the use of next-generation tyrosine kinase inhibitors based on measurable residual disease has the potential to avoid hematopoietic stem cell transplantation in treatment for adults with Philadelphia chromosome-positive acute lymphoblastic leukemia.
    Xie M; Shi T; Jiang Q; Jia Y; Zhou D; Tong H; Jin J; Zhu HH
    Cancer; 2023 May; 129(10):1523-1536. PubMed ID: 36882308
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Current Approaches to Philadelphia Chromosome-Positive B-Cell Lineage Acute Lymphoblastic Leukemia: Role of Tyrosine Kinase Inhibitor and Stem Cell Transplant.
    Kim K; Jabbour E; Short NJ; Kebriaei P; Kantarjian H; Ravandi F
    Curr Oncol Rep; 2021 Jun; 23(8):95. PubMed ID: 34125415
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Treatment Selection for Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia in the Era of Tyrosine Kinase Inhibitors.
    Ma Y; Zhang Q; Kong P; Xiong J; Zhang X; Zhang C
    Chemotherapy; 2019; 64(2):81-93. PubMed ID: 31390613
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Allogeneic Stem Cell Transplantation versus Tyrosine Kinase Inhibitors Combined with Chemotherapy in Patients with Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia.
    Wang J; Jiang Q; Xu LP; Zhang XH; Chen H; Qin YZ; Ruan GR; Jiang H; Jia JS; Zhao T; Liu KY; Jiang B; Huang XJ
    Biol Blood Marrow Transplant; 2018 Apr; 24(4):741-750. PubMed ID: 29247779
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Prophylactic or preemptive tyrosine kinase inhibitor therapy after allogeneic hematopoietic cell transplantation for Philadelphia chromosome-positive acute lymphoblastic leukemia.
    Nakasone H
    Int J Hematol; 2023 Aug; 118(2):183-192. PubMed ID: 36807259
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Comparison of allogeneic hematopoietic stem cell transplantation and TKI combined with chemotherapy for adult philadelphia chromosome positive acute lymphoblastic leukemia: a systematic review and meta-analysis.
    Zeng Q; Xiang B; Liu Z
    Cancer Med; 2021 Dec; 10(24):8741-8753. PubMed ID: 34761879
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The impact of tyrosine kinase inhibitors on allogeneic hematopoietic stem cell transplantation for adult patients with Philadelphia chromosome-positive acute lymphoblastic leukemia.
    Zhang Y; Feng S
    Leuk Res; 2021 Oct; 109():106647. PubMed ID: 34325192
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Impact of tyrosine kinase inhibitors on minimal residual disease and outcome in childhood Philadelphia chromosome-positive acute lymphoblastic leukemia.
    Jeha S; Coustan-Smith E; Pei D; Sandlund JT; Rubnitz JE; Howard SC; Inaba H; Bhojwani D; Metzger ML; Cheng C; Choi JK; Jacobsen J; Shurtleff SA; Raimondi S; Ribeiro RC; Pui CH; Campana D
    Cancer; 2014 May; 120(10):1514-9. PubMed ID: 24501014
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Allogeneic Hematopoietic Stem Cell Transplantation, Especially Haploidentical, May Improve Long-Term Survival for High-Risk Pediatric Patients with Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia in the Tyrosine Kinase Inhibitor Era.
    Xue YJ; Cheng YF; Lu AD; Wang Y; Zuo YX; Yan CH; Wu J; Sun YQ; Suo P; Chen YH; Chen H; Jia YP; Liu KY; Han W; Xu LP; Zhang LP; Huang XJ
    Biol Blood Marrow Transplant; 2019 Aug; 25(8):1611-1620. PubMed ID: 30537550
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Relapse Prevention with Tyrosine Kinase Inhibitors after Allogeneic Transplantation for Philadelphia Chromosome-Positive Acute Lymphoblast Leukemia: A Systematic Review.
    Warraich Z; Tenneti P; Thai T; Hubben A; Amin H; McBride A; Warraich S; Hannan A; Warraich F; Majhail N; Kalaycio M; Anwer F
    Biol Blood Marrow Transplant; 2020 Mar; 26(3):e55-e64. PubMed ID: 31557532
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Impact of Additional Cytogenetic Abnormalities in Adults with Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia Undergoing Allogeneic Hematopoietic Cell Transplantation.
    Aldoss I; Stiller T; Cao TM; Palmer JM; Thomas SH; Forman SJ; Pullarkat V
    Biol Blood Marrow Transplant; 2015 Jul; 21(7):1326-9. PubMed ID: 25842050
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Impact of tyrosine kinase inhibitors on patient outcomes in Philadelphia chromosome-positive acute lymphoblastic leukaemia.
    Gruber F; Mustjoki S; Porkka K
    Br J Haematol; 2009 Jun; 145(5):581-97. PubMed ID: 19388927
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Tyrosine kinase inhibitors improve long-term outcome of allogeneic hematopoietic stem cell transplantation for adult patients with Philadelphia chromosome positive acute lymphoblastic leukemia.
    Brissot E; Labopin M; Beckers MM; Socié G; Rambaldi A; Volin L; Finke J; Lenhoff S; Kröger N; Ossenkoppele GJ; Craddock CF; Yakoub-Agha I; Gürman G; Russell NH; Aljurf M; Potter MN; Nagler A; Ottmann O; Cornelissen JJ; Esteve J; Mohty M
    Haematologica; 2015 Mar; 100(3):392-9. PubMed ID: 25527562
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Dasatinib-induced complete molecular response after allogeneic hematopoietic stem cell transplantation in Philadelphia chromosome-positive acute lymphoblastic leukemia resistant to prior imatinib-containing regimen: a case report and discussion.
    Czyz A; Lewandowski K; Kroll R; Komarnicki M
    Med Oncol; 2010 Dec; 27(4):1123-6. PubMed ID: 19885746
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Current management of adult Philadelphia chromosome-positive acute lymphoblastic leukemia].
    Onizuka M
    Rinsho Ketsueki; 2018; 59(10):2028-2035. PubMed ID: 30305505
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The emerging use of chemotherapy-free regimens in adults with Philadelphia chromosome-positive acute lymphoblastic leukemia.
    Sawyers JD; Jammal NJ; Short NJ; Kantarjian H; Jabbour EJ
    Clin Adv Hematol Oncol; 2023 Feb; 21(2):68-75. PubMed ID: 36780472
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Combination chemotherapy plus dasatinib leads to comparable overall survival and relapse-free survival rates as allogeneic hematopoietic stem cell transplantation in Philadelphia positive acute lymphoblastic leukemia.
    Chang J; Douer D; Aldoss I; Vahdani G; Jeong AR; Ghaznavi Z; Zhang S; Yaghmour G; Lee KJ; Weissman A; Akhtari M
    Cancer Med; 2019 Jun; 8(6):2832-2839. PubMed ID: 31016870
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Allogeneic transplantation for patients with Philadelphia chromosome positive acute lymphoblastic leukemia: Is it imperative in the tyrosine kinase inhibitor era?
    Litzow MR
    Best Pract Res Clin Haematol; 2018 Dec; 31(4):357-360. PubMed ID: 30466747
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Adult Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia in Daily Practice: A Multicenter Experience.
    Tekgündüz E; Göker H; Kaynar L; Sarı İ; Pala Ç; Doğu MH; Öztürk E; Turgut B; Korkmaz S; Tetik A; Büyükaşık Y; Hacıoğlu SK; Bozdağ SC; Özdemir E; Altuntaş F
    Clin Lymphoma Myeloma Leuk; 2016 May; 16(5):269-74. PubMed ID: 26927932
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.